Fusion Antibodies plc (AIM:FAB)

London · Delayed Price · Currency is GBP · Price in GBX

9.50

-0.50 (-5.00%)

Oct 12, 2026, 1:44 PM GMT

Market Cap	11.89M -30.3%
Revenue (ttm)	2.11M +7.4%
Net Income	-1.15M
EPS	-0.01
Shares Out	125.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,095
Open	10.50
Previous Close	10.00
Day's Range	9.50 - 10.50
52-Week Range	9.00 - 20.00
Beta	1.28
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 14, 2026

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cell line development and cGMP scale up services. Its products are used in... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 27

Stock Exchange London Stock Exchange AIM

Ticker Symbol FAB

Full Company Profile

Financial Performance

In fiscal year 2026, Fusion Antibodies's revenue was 2.11 million, an increase of 7.38% compared to the previous year's 1.97 million. Losses were -1.15 million, -29.34% less than in 2025.

Financial Statements